2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Cardiovascular disease and cancer are the 2 leading causes of death worldwide. Emerging
evidence suggests common mechanisms between cancer and cardiovascular disease …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the
population have led to an increasing number of cancer patients presenting with acute CV …

Owing to recent advances in early reperfusion strategies, pharmacological therapy,
standardized care, and the identification of vulnerable patient subsets, the prognosis of …

Cardiovascular disease (CVD) and cancer are the leading causes of death worldwide. With
an increasing number of the elderly population, and early cancer screening and treatment …

Cancer patients and survivors have elevated cardiovascular risk when compared with
noncancer patients. Cardio-oncology has emerged as a new subspecialty to comanage and …

Aims Primary percutaneous coronary intervention (pPCI) is the gold standard, guideline-
recommended revascularization strategy in patients presenting with ST-elevation …

Patients with cancer have an increased risk of venous-and arterial thromboembolism
(VTE/ATE). Anti-cancer treatments including surgery, radiotherapy, and certain …

Aim Expected 1‐year survival is essential to risk stratification of patients with heart failure
(HF); however, little is known about the 1‐year prognosis of patients with HF and cancer …